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Abstract
Recent studies have suggested a role for the small GTPase RhoB in the control of processes required for
angiogenesis. However, the mechanisms whereby RhoB exerts control over these processes are not well
understood. Given the role of vascular endothelial growth factor (VEGF) in pathological angiogenesis, we were
interested in examining whether RhoB contributed to VEGF-induced angiogenic processes. To assess this, RhoB was
specifically depleted in human umbilical vein endothelial cells (HUVEC), using siRNA-targeted strategies. The effects
of RhoB depletion on VEGF-induced angiogenic activities were assessed using a variety of standard in vitro
angiogenesis assays to assess endothelial cell viability, migration and capillary morphogenesis. Effects of RhoB
depletion on signaling from other Rho family member proteins was also assessed using specific activity assays for
RhoA and RhoC. We observed that although RhoB appeared dispensable for HUVEC viability, RhoB was required for
endothelial cell migration, sprouting, and capillary morphogenesis. We also observed that siRNA-mediated
depletion of RhoB in HUVEC resulted in increased RhoA activation in response to VEGF stimulation. This increased
RhoA activation contributed to the cellular morphogenesis defects observed in RhoB-depleted cells, as inhibition of
RhoA activity using C3 transferase, or inhibition of the activity of the downstream RhoA effectors Rho-dependent
kinases I and II (ROCK I and II) led to a partial restoration of capillary morphogenesis in the absence of RhoB. Thus
our data indicate that RhoB plays a significant role in VEGF-induced endothelial cell morphogenesis in part by
negatively regulating the activity of RhoA and the RhoA/ROCK pathway.
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Background
Angiogenesis is a normal process involved in develop-
ment, reproduction, and wound healing, as new blood
v e s s e l sa r ef o r m e df r o mt h ep r e-existing vasculature.
Despite being a beneficial event under certain circum-
stances, angiogenesis is also a major contributing factor
to several diseases including, rheumatoid arthritis, cancer,
and ocular diseases such as diabetic retinopathy
(reviewed in [1-3]). Angiogenesis is a multi-step event
that requires growth factor stimulation of endothelial
cells, resulting in cellular proliferation, migration, tube
formation, and finally stabilization of the new vessels. As
angiogenesis only initiates following angiogenic growth
factor stimulation, many strategies that target primary
angiogenic factors, such as vascular endothelial cell
growth factor (VEGF) or its angiogenic receptor
(VEGFR) have been developed and are at various stages
of clinical testing. Although these types of anti-angio-
genic therapies have shown some ability to control dis-
ease in certain settings, recent studies have highlighted
an increased risk of severe side effects with the widely
used anti-angiogenic, Bevacizumab (reviewed in [4-6]).
For reasons such as this, the discovery of novel mechan-
isms controlling angiogenesis is necessary so that new
therapeutic targets can be identified.
RhoB is a member of the Ras superfamily of GTPases,
which includes proteins such as Rac1, Cdc42, RhoA, and
RhoC. Rho family proteins (with the exception of RhoE)
are GTPases that function by cycling through a GTP-
bound activated state and a GDP-bound inactive state.
Regulation of these states is achieved through GTPase-
activating proteins (GAPs), guanine nucleotide exchange
factors (GEFs), and guanine nucleotide dissociation inhi-
bitors (GDIs) [7]. RhoB shares ~80% homology with its
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its subcellular localization was found to be very different,
with almost exclusive localization to the cytosolic face of
early endosomes and pre-lysosomal compartments [8].
This suggested a role in receptor trafficking, and indeed
RhoB has been shown to control trafficking of a number
of growth factor receptors including platelet derived
growth factor receptor (PDGFR) [9], and epidermal
growth factor receptor (EGFR) [10]. RhoB can contribute
to growth factor receptor signaling, as it has been shown
to be required for the PDGFR-driven migration of vascu-
lar smooth muscle cells via its ability to activate and traf-
f i ce n d o s o m eb o u n dC d c 4 2t ot h ec e l lp e r i p h e r y[ 9 ] .
RhoB has also been shown to regulate whether EGF-
bound EGFR remains in early endosomes or is trans-
ported to late endosomes for degradation, and in this
manner can control duration of receptor signaling [10].
Thus, as a regulator of growth factor receptor activity,
RhoB may play a significant role in mediating growth fac-
tor-induced angiogenesis.
Given its expanding role in regulating signals from
angiogenic growth factor receptors, we were interested in
examining the effect of RhoB on various angiogenic pro-
cesses in general, and on its ability to modulate angiogenic
processes induced by the primary disease-associated
angiogenic factor VEGF. We hypothesized that RhoB
would be required for VEGF-induced capillary morpho-
genesis and that the absence of RhoB would result in
impaired angiogenic activities in endothelial cells. We
found that VEGF stimulation upregulated expression of
RhoB in endothelial cells. We also observed that although
the absence of RhoB did not affect endothelial cell viabi-
lity, RhoB was critically important for VEGF-induced
endothelial cell migration and sprout formation. We
further show that lack of RhoB in endothelial cells results
in upregulation of RhoA activity, and that suppression of
this activity or the activity of Rho-associated kinase
(ROCK) restored VEGF-induced endothelial cell capillary
morphogenesis in the absence of RhoB. We thus conclude
that RhoB is required to control RhoA activity in response
to VEGF stimulation to allow organization of endothelial
cells during endothelial cell sprouting and capillary
morphogenesis.
Methods
Antibodies, growth factors, and inhibitors
The following antibodies were used in this study: RhoB
(C-5, SC-8048), RhoA (26 C4, SC-418), and RhoC (37, SC-
130339) were all from Santa Cruz Biotechnology, Inc.
(Santa Cruz, CA), monoclonal anti-b-Actin antibody
(clone AC-74) (A5316; Sigma-Aldrich Co., St. Louis, MO),
goat anti-mouse IgG horse radish peroxidase (HRP) conju-
gate (DC02L; Calbiochem, EMD Biosciences, La Jolla, CA).
Recombinant human VEGF165 was purchased from R&D
Systems (Minneapolis, MN). Cell permeable Rho Inhibitor
was purchased from Cytoskeleton, Inc. (Denver, CO).
ROCK I/II inhibitors H-1152 and Y-27632 were purchased
from Calbiochem (EMD Biosciences, La Jolla, CA) and
dissolved in dimethyl sulfoxide (DMSO).
Cell culture
Human umbilical vein endothelial cells (HUVEC) were
purchased from Lonza and passaged in EBM-2 endothelial
cell basal media supplemented with EGM-2 SingleQuots,
both from Lonza (Walkersville, MD), to make EGM-2
growth media. Gibco MCDB 131 was purchased from
Invitrogen (Carlsbad, CA) and supplemented with L-gluta-
mine. Where appropriate, MCDB 131 was supplemented
with fetal bovine serum (FBS, Medicorp, Montreal, QC).
Experiments were routinely performed with HUVEC at P6
to P10.
siRNA transfection
For silencing of RhoB in HUVEC, two small interfering
RNAs (siRNAs) were designed as ON-TARGET reagents
from Dharmacon, Inc. (Lafayette, CO). Target sequences
were as follows: RhoB siRNA 1: UGCUGAUCGUGUU-
CAGUAA, and RhoB siRNA 2: CCGUCUUCGAGAA-
CUAUGU. Control siRNA was also purchased from
Dharmacon, Inc. (siControl Non-Targeting siRNA #1; D-
001210-01). For silencing experiments, RhoB siRNAs and
control siRNA were used at 20 nM concentration and
introduced to cells via Oligofectamine Transfection
Reagent (Invitrogen, Carlsbad, CA). Cells were analyzed
for protein knockdown and siRNA targeting RhoB was
seen to cause maximal depletion of RhoB protein at 48 h
post transfection.
Western blotting
Western blotting was performed with NuPAGE
® 4-12%
Bis-Tris gels (Invitrogen, Carlsbad, CA). Protein detection
was achieved using Immobilon Western Chemilumines-
cent HRP Substrate (Millipore, Billerica, MD), and images
were acquired with the GeneGnome imaging system (Syn-
gene, Frederick, MD).
Cell viability
siRNA-transfected or mock-transfected HUVEC were
seeded into 6-well tissue culture plates at 1 × 10
5 cells/
well and sustained in EGM-2 growth media. Viability was
assessed by trypan blue exclusion using a Vi-Cell XR cell
viability analyzer (Beckman Coulter, Brea, CA) at the
times indicated.
Migration assay
Cell migration was assessed via scratch wound assay.
Briefly, HUVEC were grown to 100% confluence and a
wound of approximately 1.5 mm was made creating a
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ments, wounding was performed at 48 h post transfec-
tion when RhoB depletion was maximal, and images
were taken at time of wounding and 24 h post wound-
ing with a Nikon Eclipse TE2000-U microscope. Cells
were incubated in MCDB 131 with 0.05% FBS and 50
ng/ml VEGF during the course of the experiment. Per-
cent wound closure was calculated from 12 total mea-
surements taken across the entire wound front in
duplicate dishes.
Sprouting assay
Fibrillar collagen I gels were generated following renatura-
tion of PureCol
® purified bovine dermal collagen
(Advanced BioMatrix, San Diego, CA) as described by the
manufacturer. Following overnight incubation to allow
gels to solidify, gel surfaces were washed and briefly incu-
bated in media prior to seeding cells at 1 × 10
5 cells per
6 cm dish in EGM-2 growth media supplemented with
50 ng/ml VEGF. Vessel sprouts were counted in a blinded
fashion, every two days from duplicate dishes. Counts
were made from 10 random fields of view per dish using
an Olympus CK2 microscope. Media supplemented with
VEGF was replaced every two days for the duration of the
assay.
Capillary morphogenesis
The organization of HUVEC into capillary-like networks
(cords) was assessed by plating cells onto Cultrex
® Base-
ment Membrane Extract (BME, Growth factor reduced,
Trevigen, Gaithersburg, MD). BME was polymerized at
37 C for 30 min in 24-well plates and cells were seeded at
5×1 0
4 in EGM-2 growth media. Twenty-four hours later,
images were taken with a Nikon Eclipse TE2000-U micro-
scope. Demarcation of each well into quadrants allowed
for a total of 4 images per well with the total number of
capillary-like cords in each image counted with ImageJ
software, and expressed as the average number of cords
per field of view. Percent decreases were also determined
following normalization of mean cord count for RhoB
depleted cells to their respective control siRNA transfected
cells under each condition (e.g. in absence or presence of
each specific inhibitor).
Rho activation assays
Levels of activated RhoA were determined using the
RhoA G-LISA™ Activation Assay kit (Cytoskeleton Inc.,
Denver, CO), according to the manufacturer’si n s t r u c -
tions. Briefly, siRNA-transfected HUVEC were serum
starved in MCDB 131 for 5 h at 48 h post transfection.
Cells were then treated with 10 ng/ml VEGF for the
times indicated and protein lysates were collected and
frozen at -80 C for subsequent analysis. Protein lysates
were then run on G-LISA™ plates using RhoA specific
antibody for detection of captured active RhoA according
to the manufacturer’s directions, and absorbance was
determined with a Multiskan Ascent photometer
(Thermo Scientific, Rockford, IL). In all cases, constitu-
tively active RhoA protein provided in the G-LISA™ kit,
was used as a positive control to validate that the assay
was functioning appropriately.
For detection of levels of active RhoC, the G-LISA™ kit
was again used according to the manufacturer’si n s t r u c -
tions with the exception that a RhoC specific antibody was
used to detect the amount of captured active RhoC. For
the detection of RhoC, siRNA-transfected HUVEC were
starved in MCDB 131 (0.5% serum) overnight, followed by
starvation in serum-free MCDB 131 for 4 h. Cells were
then treated with 50 ng/ml VEGF (hence stimulated 48 h
post-siRNA transfection) and lysates collected 5 min post-
VEGF stimulation. For the detection of activated RhoB,
the G-LISA™ kit was used according to the manufac-
turer’s instructions with the exception that a RhoB specific
antibody was used to detect the amount of active RhoB
captured on the plate. Activated RhoB was detected in
HUVEC protein lysates collected at various times post sti-
mulation of overnight serum starved cells (in MCDB 131
with 0.5% FBS), and their subsequent stimulation with
20 ng/ml VEGF.
Results
R h o Bh a sb e e ns h o w nt op l a yar o l ei ng r o w t hf a c t o r
receptor trafficking and through this mechanism can regu-
late growth factor receptor signaling under certain circum-
stances [9,10]. With this in mind, we became interested in
determining whether RhoB regulated VEGF-induced
angiogenic processes in endothelial cells, in order to iden-
tify possible novel targets which might ultimately be useful
for enhancing the efficacy of current anti-VEGF/VEGFR
blocking strategies. We thus used small interfering (si)
RNA silencing strategies in human umbilical vein
endothelial cells (HUVEC) to determine the effects of
reduced RhoB expression on the ability of VEGF to induce
endothelial cell proliferation or morphogenesis, and by
what potential mechanisms RhoB may regulate these
angiogenic processes.
VEGF upregulates expression of RhoB
Our initial studies focused on characterizing the expres-
sion of RhoB in HUVEC as a model cell system. We
found that HUVEC expressed readily detectable levels of
endogenous RhoB (Figure 1A). Moreover, VEGF treat-
ment of HUVEC resulted in increased RhoB protein
levels within 8 h post-stimulation, with protein reaching
maximal expression around 12 h post-VEGF stimulation
(Figure 1A). To determine if increased RhoB protein
levels were associated with concomitant increases in
RhoB activity in these cells, we utilized the G-LISA™
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RhoA. This assay utilizes the Rho effector protein Rho-
teckin for binding activated RhoA, and as Rhoteckin also
binds RhoB, albeit much less efficiently [11], we utilized
the same G-LISA™ assay but modified it for detection of
the pulled-down active RhoB by using a RhoB specific
monoclonal antibody for detection. Using this modified
assay, we found that HUVEC do not show increased
levels of active RhoB following VEGF stimulation (Figure
1B), even at time points where increased levels of RhoB
protein are observed (Figure 1A).
Depletion of RhoB levels in HUVEC inhibits cell migration
but does not affect cell viability
In order to assess the contribution of the small GTPase
RhoB to processes important to angiogenesis, we
employed a siRNA strategy to specifically deplete levels
of RhoB in HUVEC. Two siRNAs directed to RhoB
were validated for sequence specificity and used at 20
nM concentration to effectively reduce protein levels of
RhoB in HUVEC. When compared to mock transfected
and control siRNA transfected cells, there was an evi-
dent reduction in RhoB protein levels, as detected by
western blot analysis, at 48 h post-siRNA transfection
(Figure 2A).
As cell survival and migration are both important
requirements for angiogenesis to occur, we next exam-
ined whether depleting RhoB affected either of these
two processes. RhoB levels were thus depleted using two
independent specific RhoB targeting siRNA constructs,
Figure 1 Vascular endothelial growth factor (VEGF) stimulation
results in increased expression but not activity of RhoB protein
in HUVEC. (A) RhoB protein levels are increased following VEGF
stimulation. Cells were serum starved overnight in MCDB 131 with
0.25% FBS. Following this, media was replaced with MCDB 131 with
0.25% FBS and 20 ng/ml VEGF, and protein lysates were collected at
the times indicated. Protein lysates were subjected to western
blotting and total levels of RhoB protein were assessed. b-actin was
used as a total protein loading control. (B) Levels of activated RhoB
do not change following VEGF stimulation. Cells were serum starved
overnight in MCDB 131 with 0.5% FBS, followed by stimulation with
20 ng/ml VEGF. At various times post-VEGF stimulation, protein
lysates were collected and activated RhoB was assessed using G-
LISA assays as described in Materials and Methods. Bars represent
the mean ± SEM for duplicate measures in each of two
independently performed experiments.
Figure 2 siRNA-mediated RhoB depletion inhibits endothelial
cell migration but not viability. (A) Efficient depletion of RhoB
protein levels was achieved in HUVEC with small interfering RNA
treatment. HUVEC were either mock transfected with PBS (M) or
transfected with 20 nM of the indicated siRNAs [Control (C), RhoB
siRNA 1, RhoB siRNA 2]. Cellular total protein lysates were collected
at 48 h post transfection and analyzed for levels of RhoB by western
blot. Levels of b-actin served as a protein loading control. (B)
Assessment of cell viability in RhoB-depleted HUVEC. Cells were
either mock transfected with PBS or transfected with siRNAs, as
indicated, and number of viable cells were assessed following
trypan blue exclusion and counting with a Beckman Coulter Vi-Cell
XR analyzer in triplicate wells at each time point. Data presented
shows mean ± SD of two independently performed experiments.
(C) RhoB-depletion inhibits cell migration. A scratch wound assay of
transfected HUVEC was performed in MCDB 131, with 0.05% FBS
and 50 ng/ml VEGF. Images depict wound size at time of wounding
(Time = 0 h) and 24 h later. (D) Analysis of cell migration from (C).
Bars represent the mean ± SD for percent wound closure, after 24 h
for a representative experiment. P values were calculated using a
two-tailed unpaired student’s t test (* P < 0.05).
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over time following quantification of viable cell numbers
using trypan blue exclusion. We observed no significant
difference in HUVEC growth or viability between RhoB-
depleted and control siRNA treated cells (Figure 2B).
Cell migration was also assessed using a scratch wound
assay. HUVEC were transfected with either RhoB-tar-
geted siRNA or non-targeting control siRNA at concen-
trations of 20 nM and subsequently, the confluent
HUVEC monolayer was ‘scratched’ and photographed to
determine wound diameter at time 0. Media was then
replaced with MCDB 131 minimal media with 0.05%
FBS and supplemented with 50 ng/ml VEGF, thus mak-
ing migration of HUVEC essentially VEGF-dependent.
Cells were then allowed to migrate and fill the wound
over the course of 24 h, at which time wound diameters
were re-photographed and the percent wound closure in
each condition was determined. When assessed in this
manner, reduced levels of RhoB resulted in significant
inhibition of cell migration as indicated by decreased
percent wound closure after 24 h as compared to con-
trol siRNA transfected cells (Figure 2C and 2D). Taken
together, our data suggest that RhoB plays an important
role in modulating VEGF-induced cell migration signals,
while appearing to be dispensable for VEGF-induced
proliferative signals in endothelial cells.
siRNA-mediated depletion of RhoB reduces HUVEC
capillary sprouting and morphogenesis
To assess the importance of RhoB to HUVEC luminal
vessel-like formation we first utilized a collagen gel-
based assay. In this assay cells are placed onto a collagen
I matrix and induced to sprout with VEGF, resulting in
polarized vessel-like structures that contain lumen.
RhoB was silenced in HUVECs using the targeted siR-
NAs, and 24 h later transfected HUVEC were plated on
collagen I gels where they were subsequently stimulated
with 50 ng/ml VEGF in EGM-2 growth medium. Sprout
structures were then counted over a period of 10 days.
We observed a statistically significant reduction in the
number of vessel structures generated by RhoB siRNA-
treated HUVEC when compared to cells treated with
non-targeting control siRNA or mock transfected cells
in response to VEGF stimulation (Figure 3A). We also
assessed the ability of RhoB-depleted cells to form capil-
lary-like networks on basement membrane extract
(BME). In this assay, which is commonly used to test
the angiogenic potential of endothelial cells, cells will
usually elongate and align to form a network of cord
structures that are devoid of lumens. When these cord
structures were quantified, RhoB appeared to be
required for HUVEC capillary morphogenesis in this
assay, with HUVEC depleted of RhoB showing
significant reduction in the number of cord structures
formed as compared to control transfected cells (Figure
3B). It should be noted however, that the cord struc-
tures that did form in RhoB-depleted cells were similar
in morphology to those observed in control-treated cells
Figure 3 Depletion of RhoB inhibits in vitro vessel sprouting
and capillary morphogenesis. (A) RhoB-depleted HUVEC have
reduced ability to form vessel sprouts on collagen I gels. Cells were
either mock transfected with PBS or transfected with 20 nM siRNAs
(Control, RhoB siRNA 1, RhoB siRNA 2) as indicated and seeded onto
collagen I gels at 24 h post transfection. At time zero (48 h post-
siRNA transfection), cells were placed in EGM-2 growth media
supplemented with 50 ng/ml VEGF to induce sprouting. Media
supplemented with VEGF was refreshed every two days. Blinded
counts were made from 10 random fields of view from each of
duplicate plates, and compiled data are presented as mean ± SE of
duplicate dishes from each of two independently performed
experiments. Significance was determined by unpaired t-tests relative
to control siRNA at each respective time point (* represents p < 0.05
and ** represents p < 0.0001) (B) Depletion of RhoB levels inhibit
capillary morphogenesis. HUVEC were transfected with siRNAs as
indicated and seeded onto polymerized basement membrane
extract (BME) in EGM-2 growth media. Images were taken 24 h after
cell seeding and capillary morphogenesis was determined by
averaging the total number of cord-like structures in 4 fields of view
as assessed with ImageJ software. The data is presented as the mean
± SE of two independently performed experiments. Significance was
determined by ANOVA with Fisher’s PLSD post hoc analysis (*
represents p < 0.05 and ** represents p < 0.0001).
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incomplete RhoB depletion in 100% of cells.
HUVEC depleted of RhoB show increased levels of
activated RhoA in response to VEGF treatment
As the primary defect we observed in RhoB-depleted
HUVEC was an inability to migrate and form capillary-
like structures, we focused on a role for RhoB in modu-
lating targets that regulate these pathways. Interestingly,
studies have indicated that Rho protein family members
can regulate one another through various mechanisms
[9,12,13]. Specifically, evidence exists for unidirectional
regulation of RhoB protein stability by RhoA [14]. These
facts combined with the knowledge that RhoA plays an
important role in cell migration led us to test whether
RhoB counter-regulated RhoA, which could thus affect
downstream directed cell migration and capillary mor-
phogenesis. In order to assess the activation status of
RhoA, control or RhoB-targeted siRNA transfected
HUVEC were stimulated with VEGF (10 ng/ml), and pro-
tein extracts were generated over time post-VEGF stimu-
lation to assess RhoA activity through the G-LISA™
activation assay kit as described in materials and meth-
ods. The concentration of VEGF used in this assay has
previously been shown to induce RhoA activity in
HUVECs [15], and under these conditions, we observed
increases in RhoA activity in control siRNA treated cells
as a result of VEGF stimulation alone (Figure 4A, com-
pare 0 min to 30 min time points). However, RhoA acti-
vation observed in RhoB-depleted cells at the same time
points was significantly greater than in controls (Figure
4A). It should also be noted, that even at the 0 time
point, there was a modest basal increase in RhoA activity
in RhoB-depleted cells compared to control cells even in
the absence of VEGF stimulation (Figure 4A), supporting
our hypothesis that the presence of functional RhoB may
suppress RhoA activity. In addition, we also looked at the
activity of RhoC, another Rho family member that has
recently been indicated to play a role in endothelial cell
migration and vessel organization [16]. We once again
utilized the G-LISA™ activation kit; this time modifying
it for use in detection of RhoC instead of RhoA through
use of a RhoC specific monoclonal antibody. Interest-
ingly, in contrast to our observations for RhoA, RhoB
siRNA-treated cells had reduced levels of active RhoC in
serum starved HUVECs, although this did not quite
reach statistical significance (Figure 4B). We also evalu-
ated the total protein levels of RhoA and RhoC by wes-
tern blot analysis and observed no significant changes in
their expression levels in HUVEC that were clearly
depleted of RhoB by two different siRNAs (Figure 4C).
Hence the differences observed using the G-LISA™ are
indicative of differential regulation of activity of RhoA
and RhoC by RhoB expression in response to VEGF
stimulation.
Inhibiting RhoA activity can partially restore capillary
morphogenesis in RhoB-depleted HUVEC
In order to determine if the increased RhoA activity seen
in cells depleted of RhoB contributed to the defects in
capillary morphogenesis observed in RhoB-depleted cells,
we inhibited the elevated RhoA activity in RhoB depleted
cells and evaluated whether capillary-like network forma-
tion could be restored under these conditions. Given that
we did not see significant changes in the total levels of
RhoA protein, but only its activity in RhoB-depleted cells,
we did not want to alter the total levels of RhoA within
the cell by using a technique such as siRNA, and thus
chose to pharmacologically inhibit RhoA activity. To this
end, we administered the cell permeable Rho inhibitor
C3 transferase. C3 transferase is an ADP ribosyltransfer-
ase that selectively ribosylates Rho proteins, rendering
them inactive. Although C3 transferase does have inhibi-
tory function against all three of the closely related Rho
family members, RhoA, RhoB, and RhoC, in the absence
of RhoB (which we have depleted with siRNA), C3 trans-
ferase will primarily inhibit RhoA and RhoC (which is
already suppressed under these conditions) in these cells.
As seen previously, RhoB-depleted HUVEC had signifi-
cantly fewer cords than control treated cells (Figure 4D
and 4E). However, when siRNA-transfected HUVEC
were plated on BME in the presence of C3 transferase,
we observed a slight increase in the number of capillary-
like cords in control siRNA-transfected cells (Figure 4D
and 4E), indicating the inhibition of Rho proteins with
C3 transferase may have a positive effect on cord forma-
tion in general in this particular assay system. Notably,
we also observed a restoration of the ability of RhoB-
depleted cells to form cord structures almost to the levels
of control siRNA-treated cells in the presence of C3
transferase (Figure 4D and 4E). Specifically, HUVEC trea-
ted with RhoB siRNAs 1 and 2 show reductions in capil-
lary cord formation of approximately 25% and 45%
respectively when compared to control cells in the
absence of inhibitor; however, treatment with C3 trans-
ferase essentially fully restores cord formation in RhoB
siRNA 1 transfected cells and restores cord formation in
RhoB siRNA 2 transfected cells to within approximately
25% of control levels. Although we cannot dismiss the
possibility that a proportion of the effects seen with C3
transferase could be due to inhibition of RhoC, it seems
unlikely that this contributes to the restoration of cord
formation, as we have shown that RhoB-depleted
HUVECs already have a lower level of activated RhoC
compared to control cells. Thus these results support a
mechanism by which increased RhoA activity contributes
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observed reduction in capillary morphogenesis. (A) G-LISA analysis indicating increased levels of activated RhoA in response to VEGF in cells
with depleted RhoB expression. Cells were transfected with the indicated siRNAs, and 48 h post transfection were serum starved for 5 h in
MCDB 131, and subsequently stimulated with 10 ng/ml VEGF in MCDB 131. At various times post-stimulation, protein lysates were generated
and activated RhoA was detected by G-LISA assays as described in Materials and Methods. Bars represent the mean ± SE of a representative
experiment performed in triplicate (* represents p < 0.05 as determined by unpaired t-tests when compared to Control siRNA samples at each
time point). Similar trends were observed in independent experiments. (B) G-LISA analysis indicating reduced RhoC activity in cells treated with
RhoB siRNAs. Cells were transfected with the indicated siRNAs (Control, RhoB siRNA 1, RhoB siRNA 2), followed by starvation overnight in MCDB
131 with reduced serum (0.5%), and for an additional 4 h in MCDB 131 (0% serum). Cells were subsequently stimulated with 50 ng/ml VEGF in
MCDB 131 for 5 min and protein lysates were generated for analysis of RhoC activity (at 48 h post-siRNA transfection) by G-LISA as described in
Materials and Methods. Bars indicate the mean ± SE for duplicate measures in each of two independently performed experiments. (C) Protein
levels of RhoA and RhoC were assessed in RhoB siRNA-treated HUVEC. Cells were transfected with 20 nM of the indicated siRNAs and lysates
collected at 48 h post transfection. Protein levels were analyzed by western blotting, with levels of b-actin serving as a control for protein
loading. (D) Defective capillary morphogenesis in RhoB depleted HUVEC is restored upon inhibition of RhoA activity. HUVEC were transfected
with siRNAs as indicated and seeded onto BME in EGM-2 growth media in the absence or presence of 0.25 μg/ml C3 transferase or DMSO as a
vehicle control. Images are representative photos taken 24 h after cell seeding. (E) Analysis of capillary morphogenesis from (D). Capillary
morphogenesis was determined by averaging the total number of cord-like structures in 4 fields of view in triplicate wells as assessed with
ImageJ software. Bars represent the mean ± SE of duplicate wells from each of two independently performed experiments (* represents p < 0.05
and ** represents p < 0.0001 compared to control siRNA as determined by ANOVA with Fisher’s PLSD post hoc testing).
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HUVEC.
Pharmacological inhibition of rho-dependent kinases
ROCK I/II in RhoB-depleted HUVEC partially restores
capillary morphogenesis
To further support our previous findings with the C3
transferase Rho inhibitor, we examined whether targeting
pathways activated downstream of RhoA could also
restore the vessel formation defects observed in RhoB-
depleted cells. As the Rho-dependent kinases ROCK I
and ROCK II coordinate signaling events downstream of
RhoA, we targeted this pathway as a potential signaling
mechanism contributing to the impaired capillary mor-
phogenesis in RhoB-depletedc e l l s .W et h u sp l a t e dc o n -
trol or RhoB siRNA-treated HUVEC on BME in the
presence of vehicle control or two different inhibitors of
ROCK I/II activity, namely Y-27632 and H-1152. Similar
to what had been observed following use of C3 transfer-
ase, addition of either ROCK I/II inhibitor to control
siRNA transfected cells resulted in slightly enhanced
cord forming ability of HUVEC as compared to vehicle
control (Figure 5A and 5C for Y-27632; Figure 5B and
5D for H-1152). Again, similar to what we had previously
observed following treatment with C3 transferase, treat-
ment of RhoB-depleted HUVEC with either ROCK inhi-
bitor, restored cord formation in cells treated with RhoB
siRNA 1 essentially to that of control siRNA levels (Fig-
ure 5C and 5D). Cord formation was also restored in
RhoB siRNA 2 treated cells by the addition of ROCK
inhibitors where the impairment in cord formation was
reduced to only approximately 32% compared to control
cells in contrast to the approximately 43% impairment in
cord formation observed in the absence of ROCK inhibi-
tors (Figure 5C and 5D). These results lend support to
the notion that an inappropriately activated RhoA/ROCK
pathway contributes to the observed defective capillary
morphogenesis phenotype in RhoB-depleted endothelial
cells.
Discussions and conclusions
The contribution of RhoA protein signaling to processes
that are important for angiogenesis, such as proliferation,
migration, capillary morphogenesis and sprouting, has
been previously identified (reviewed in [17]), however the
contributions of the Rho family member RhoB remain less
clear. Indications from knockout murine models that
RhoB may modulate vessel sprouting in the retina of these
mice [18], along with its proposed role in the trafficking
and signaling of growth factor receptors [9,10,19,20], sug-
gested to us that RhoB may play an important role in
pathological angiogenesis directed by VEGF/VEGFR sig-
naling. As such, RhoB could potentially prove to be an
important beneficial therapeutic target for controlling
pathological angiogenesis. Although some evidence sug-
gested that RhoB could regulate endothelial cell sprouting
[18], its role in growth factor induced angiogenesis was
not thoroughly examined. With this in mind, the present
study aimed to determine if RhoB was necessary for pro-
cesses involved in VEGF-induced capillary morphogenesis,
and by what mechanisms RhoB controls these events.
Our first objective was to determine whether VEGF had
any direct effects on the regulation of RhoB, as certain
other growth factors such as transforming growth factor b
(TGF-b), and EGF have been identified as regulators of
RhoB expression in a number of human cell lines [21-23].
Interestingly, we observed increased expression of RhoB
p r o t e i ni nH U V E Cf o l l o w i n gs t i m u l a t i o nw i t hV E G F .
Results indicated a rise in protein levels between 4 and 8 h
post stimulation with levels peaking at 12 h post stimula-
tion and slowly decreasing thereafter. The mechanism
leading to increased RhoB expression after VEGF treat-
ment in HUVEC is presently unknown, and the exact
implications of raising RhoB levels in VEGF stimulated
HUVEC are not understood. However, it is likely that
increasing RhoB expression is necessary for proper
response of endothelial cells to VEGF. Indeed, transcrip-
tional induction of the RhoB gene is achieved by TGF-b in
human keratinocytes, and depletion of RhoB through
siRNA has been shown to impede TGF-b-induced migra-
tion [21], indicating the potential relevance of induced
expression in that system. Our finding that RhoB expres-
sion is induced by VEGF in endothelial cells highlights
RhoB as a potentially important regulator of VEGF signal-
ing, thus warranting future mechanistic studies.
In order to assess the importance of RhoB in angiogenic
processes, we employed a siRNA strategy to specifically
deplete HUVEC cells of RhoB,a n ds u b s e q u e n t l yd e t e r -
mined whether RhoB was necessary for endothelial cell
survival, migration, sprouting or capillary morphogenesis.
RhoB was found to be dispensable for endothelial cell sur-
vival, as depleting RhoB levels had no effect on cell growth
or viability over time. With respect to endothelial cell
migration, sprouting and capillary morphogenesis, we
found that RhoB was required for VEGF induction of
these processes. These findings are supported by work of
others in transgenic mouse or in vitro models of angiogen-
esis [18,24]. In contrast to the study by Sabatel et al. [24]
where angiogenic activities were induced by a combination
of basic fibroblast growth factor (bFGF) and VEGF
together, our study focused specifically on VEGF-induced
angiogenic processes. As such, our work supports a signifi-
cant role for RhoB in modulating HUVEC migration and
capillary morphogenesis in response to VEGF, a main
mediator of angiogenesis in pathological settings.
Our results suggest that RhoB contributes to VEGF-
induced endothelial cell capillary morphogenesis in part
via its ability to negatively regulate RhoA. Historically,
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endothelial cells [15] and to contribute, along with other
Rho family members, to the regulation of angiogenesis
(reviewed in [17]). Our results now show that VEGF upre-
gulation of RhoB plays a role in the negative regulation of
RhoA activity, as when RhoB was absent, even low con-
centrations of VEGF induced substantial increases in
RhoA activity, a phenomenon that did not occur when
RhoB was present. These results thus suggest that RhoB
may be important for limiting endothelial cell response to
insignificant levels of VEGF that could otherwise lead to
an inappropriately timed angiogenic response. Cross-regu-
lation between Rho family members has been previously
suggested. The family member Rac has been shown to reg-
ulate the activity of RhoA in fibroblasts, resulting in con-
trol of cell morphology and migration [13]. More recently,
RhoA phosphorylation has been noted to release Rac from
binding to RhoGDIalpha, resulting in translocation of Rac
to the cell periphery followed by its activation [12]. Addi-
tionally, RhoB has been noted to traffic Cdc42 to the cell
membrane in response to platelet-derived growth factor
stimulation, and thus contribute to signaling necessary for
cell movement [9]. Our data indicate that RhoB also nega-
tively regulates the level of RhoA activation in response to
VEGF. We further demonstrate that this inhibition of
RhoA activity by RhoB is necessary for proper endothelial
cell capillary morphogenesis. Moreover, activation of the
RhoA/ROCK pathway has been shown to inhibit angio-
genic processes [25,26], thus lending support to our obser-
vations that the absence of RhoB results in impaired
angiogenic activities in part via uncontrolled RhoA/ROCK
activation.
Given our results suggesting that RhoB negatively
regulated RhoA activity, we were also interested to
Figure 5 Inhibition of ROCK partially restores capillary morphogenesis in RhoB-depleted HUVEC. Cells were transfected with siRNAs as
indicated and seeded onto BME in EGM-2 growth media in the absence or presence of (A) 10 μM Y-27632 or (B) 1 μM H-1152. In both cases,
control media conditions contained EGM-2 growth media with equivalent volumes of DMSO as a vehicle control. Images were taken 24 h after
cell seeding. (C, D) Analysis of capillary morphogenesis from (A, B). Capillary morphogenesis was determined by averaging the total number of
cord-like structures in 4 fields of view as assessed with ImageJ software. Bars represent the mean ± SE of duplicate wells from each of two
independently performed experiments (* represents p < 0.05 and ** represents p < 0.0001 as compared to the control siRNA sample using
unpaired t-tests).
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activity of other Rho family members. To this end, we
evaluated the effects of RhoB depletion on the level of
activity of RhoC in endothelial cells. We were intrigued
to observe that in contrast to our results with RhoA
activation, RhoC activity was somewhat reduced in the
absence of RhoB. Thus together, our results suggest that
RhoB regulates the activity of RhoA and RhoC in a reci-
procal manner. Although studies with RhoC-null mice
did not indicate any angiogenic defects associated with
primary mammary tumors [27], a more recent study
showed that treatment of human dermal microvascular
cells with siRNA directed to RhoC, inhibited migration
and tube formation, suggesting that RhoC activity may
be necessary for angiogenesis under specific conditions
[16]. As RhoC can also contribute to processes such
tumorigenesis and metastasis [28,29] in addition to
angiogenesis [16], the RhoB regulation of RhoC activity
could also be of significance in tumor growth and
tumor-associated angiogenesis.
Interestingly, cross-regulation of RhoB by RhoA has
been previously suggested, as it was shown that depletion
of RhoA led to increased RhoGDIalpha binding to RhoB
thereby resulting in RhoB protein stabilization [14]. Our
study, however, demonstrates the reverse interaction,
namely that RhoB negatively regulates the activation of
RhoA to promote endothelial cell capillary morphogenesis.
It is possible that regulation in our system is achieved via
similar mechanisms as suggested by Ho et al. [14],
whereby RhoA and RhoB compete for RhoGDIalpha bind-
ing, although this has not yet been demonstrated. Indeed,
the importance of regulation among Rho family members
mediated by binding to RhoGDIs is becoming increasingly
evident, with recent studies cautioning that modulation of
one Rho protein can affect others by shifting the balance
of RhoGDI binding [30,31]. Additionally, it is becoming
more evident that Rho proteins are spatially and tempo-
rally regulated in regards to their activity [32-34]. Evidence
of a short transcript half-life for RhoB [35] indicates a high
degree of regulated expression, stressing that even the
induction of minor changes in RhoB expression could lead
to significant effects on cell signaling. Accordingly, it is
possible that when RhoB is removed, a cell can no longer
control the spatially regulated activation of RhoA, result-
ing in delocalization of RhoA-mediated signaling events
required for directed cell migration and vessel formation.
Due to their close sequence homology, RhoA and RhoB
are known to bind similar protein regulators and effec-
tors. For example, the regulator XPLN, a GEF, has been
shown to specifically interact with RhoA and RhoB, but
not RhoC [36]. As regulators such as GEFs and GAPs
undergo translocation in response to extracellular stimuli
[37,38], and in some cases to specific sites within cells
occupied by their corresponding GTPase (reviewed in
[7]), it is possible that competition between RhoB and
RhoA for these regulators of activation is responsible for
RhoB’s control over RhoA activity levels in response to
V E G F .I n d e e d ,a l t h o u g hn o td i rectly demonstrated, this
has been hypothesized as a likely means of RhoB cross-
regulation [39]. However, our data suggests that RhoB
negatively regulates RhoA, but appears to have a positive
regulatory function with respect to RhoC, suggesting that
competition for activating factors or effector proteins is
not the regulatory mechanism in place for this latter
interaction. With this in mind, future studies will be
directed towards better understanding the relationship
between RhoA, RhoB, RhoC, and the various binding
partners that may function to allow RhoB to regulate
angiogenesis.
In conclusion, we have demonstrated that depletion of
RhoB in HUVEC results in deleterious effects on pro-
cesses important to angiogenesis, such as endothelial
cell migration and capillary morphogenesis. These
defects are, in part, due to inappropriately increased
levels of activated RhoA following VEGF stimulation in
the absence of RhoB. Lack of RhoC activity may also
contribute to the observed defects. Based on these
results we suggest a novel mechanism whereby RhoB
exerts control over endothelial cell capillary morphogen-
esis through the negative regulation of RhoA and the
positive regulation of RhoC activity in response to the
pro-angiogenic growth factor VEGF.
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